{{ subpage.title }}

The race to vaccinate: Dr. Atul Gawande provides perspective

Can the US vaccinate enough of its population to prevent hundreds of thousands of deaths before new and more contagious COVID-19 variants take hold? And will these vaccines even be effective against more adaptable mutations of the virus? Surgeon and public health expert Dr. Atul Gawande, most recently of the Biden/Harris COVID-19 Transition Task Force, joins Ian Bremmer on GZERO World to discuss the latest in the global effort to vaccinate our way out of this pandemic. He also explains why people should get the Johnson & Johnson vaccine if offered the chance, despite its lower overall efficacy rate compared to the mRNA-based vaccines from Pfizer and Moderna.

Podcast: The Race to Vaccinate: Dr. Atul Gawande Provides Perspective

Listen: Can the United States vaccinate enough of its population to prevent hundreds of thousands of deaths before new and more contagious COVID-19 variants take hold? And will these vaccines even be effective against more adaptable mutations of the virus? Surgeon and public health expert Dr. Atul Gawande, most recently of the Biden/Harris COVID-19 Transition Task Force, joins the podcast to discuss the latest in the global effort to vaccinate our way out of this pandemic. He also explains why people should get the Johnson & Johnson vaccine if offered the chance, despite its lower overall efficacy rate compared to the mRNA-based vaccines from Pfizer and Moderna.

Subscribe to the GZERO World Podcast on Apple Podcasts, Spotify, Stitcher, or your preferred podcast platform to receive new episodes as soon as they're published.

A shot in the arm: Moderna’s co-founder on the COVID-19 vaccine

The pandemic's US death toll shows no signs of abating and the holiday season's spike will likely dwarf any surge that came before it. But in the midst of this dark winter there are glimmers of hope, as the first of the COVID-19 vaccines have nearly arrived (or, depending on when you read this, already have). On GZERO World, Ian Bremmer interviews Noubar Afeyan, the co-founder of a leading vaccine developer Moderna. They'll discuss distribution plans, the revolutionary science behind Moderna's vaccine, and how a company younger than Twitter became a frontrunner in the race to end the pandemic.

Podcast: COVID Vaccine in Record Time - What Now? Moderna Co-Founder Noubar Afeyan

Listen: The pandemic's US death toll shows no signs of abating and the holiday season's spike will likely dwarf any surge that came before it. But in the midst of this dark winter there are glimmers of hope, as the first of the COVID-19 vaccines have nearly arrived (or, depending on when you read this, already have). On the GZERO World podcast, Ian Bremmer interviews Noubar Afeyan, the co-founder of a leading vaccine developer Moderna. They'll discuss distribution plans, the revolutionary science behind Moderna's vaccine, and how a company younger than Twitter became a frontrunner in the race to end the pandemic.

How the Moderna vaccine works, why it’s effective, and how it’ll be distributed

"What we're trying to do is to educate the immune system to see the protein before it's seen the virus." In a race for a COVID vaccine, Moderna, a 10-year old company with no products previously on the market, developed a vaccine in 10-months, by using revolutionary new mRNA technology. Now the focus shifts to how to distribute and safely administer this vaccine. Moderna co-founder and chairman Noubar Afeyan explains.

His conversation with Ian Bremmer was part of the latest episode of GZERO World, which began airing nationally in the US on public television Friday, December 11th. Check local listings.

Watch the GZERO World episode: A Shot in the Arm: Moderna's Co-Founder on the COVID-19 Vaccine

Subscribe to GZERO Media's newsletter, Signal

Latest